RxDoctor Payments DataLook up a doctor →

David Battin, MD

Interventional Cardiology · Salina, KSNPI 1700881000

Payments from drug & device makers

$29,563in general payments, 2019–2025

Across 994 payments — averaging $29.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$14K
  • Boston Scientific$3K
  • Endologix LLC$3K
  • Novartis$1K
  • Abbott$1K
  • AstraZeneca$886
  • plus $7K from 37 others

What the payments were for

  • Travel & lodging$6,23121%
  • Food & beverage$22,92178%
  • Education$4101%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$29,563 in reported general payments places this provider in the 70th percentile of 55 interventional cardiology providers in Kansas.

See all interventional cardiology providers in Kansas

Medicare billing

Part B allowed, 2024
$473,457
Medicare patients
1,814
Services billed
7,467

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan282$228,593
EliquisApixaban254$171,116
JardianceEmpagliflozin162$118,061
Repatha SureclickEvolocumab72$76,559
XareltoRivaroxaban81$57,772
FarxigaDapagliflozin Propanediol70$46,425
MultaqDronedarone Hcl44$43,656
Praluent PenAlirocumab48$40,486
BrilintaTicagrelor40$17,769
CorlanorIvabradine Hcl11$7,480
DapagliflozinDapagliflozin Propanediol13$6,561
Rosuvastatin Calcium442$3,743
ClopidogrelClopidogrel Bisulfate269$1,909
Dabigatran EtexilateDabigatran Etexilate Mesylate11$1,864
Prasugrel Hcl46$1,748

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$1,074$228,593282 claims
PfizerEliquis$815$171,116254 claims
Boehringer IngelheimJardiance$252$118,061162 claims
AstraZenecaFarxiga, Brilinta$886$64,193110 claims
Johnson & JohnsonXarelto$644$57,77281 claims
Sanofi-aventis U.S. LLCMultaq$133$43,65644 claims
AmgenCorlanor$476$7,48011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 55 interventional cardiology providers in Kansas.

Other interventional cardiology in Salina

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →